Shantha Biotechnics Steps into Make in India Mission


Shantha Biotechnics a company owned by, Sanofi Pasteur the vaccines division of French pharma company Sanofi Group has started vaccine production in its new manufacturing unit of 19,000 sq-meters in Muppireddipalli Special Economic Zone (SEZ) near Hyderabad, India.

shantha biotechnics indiaThe plant approved by Indian regulatory authorities and the World Health Organisation is equipped with latest technologies to meet the standard quality in vaccine production.

This unit will be producing a pentavalent paediatric vaccine Shan5 that renders effective protection for children from 6 weeks of age against five diseases namely diphtheria, tetanus, pertussis, Haemophilus influenzae type B and hepatitis B and cholera vaccine Shanchol.

10 million doses of Shan 5 will be produced from this plant to cater to local needs and also to export vaccines to the United Nations Children’s Emergency Fund (UNICEF) and other international markets. However, the production capacity of the plant can be scaled up to 30 million doses per annum.

Apart from these two vaccines the company will be registered to produce Shanvac-B, a hepatitis B vaccine and the tetanus toxoid vaccine Shan TT.

The Executive Director and Chief Operating Officer of Shantha Biotechnics Mahesh Bhalgat commented, “The new facility will be used in the manufacture of two important vaccines approved by WHO – Shan5 and Shanchol. Shan5 is a five-in-one vaccine for children against five diseases, while Shanchol is used as an active immunisation against cholera. The other vaccines to be manufactured in the plant include Shan-TT, Shan-IPV and Shanvac-B.”

Sanofi’s investment of Rs 5,500 crore into Shantha Biotechnics since its acquisition in 2009 has led to the construction of yet another plant which is expected to commence its operation from 2017.

The new plant at an investment of Rs 450 crore will be Sanofi’s second Insuman manufacturing facility after Frankfurt catering to produce human insulin product Insuman, used to treat type-1 and type-2 diabetes.

Mahesh Bhalgat also said, “At Shantha Biotechnics, our mission is to develop, produce and market affordable vaccines. We are committed to providing our customers with the assurance of products that meet best-in-class international standards for purity, potency and safety.”

Leave a reply

Your email address will not be published. Required fields are marked *